Univariate analysis for NRM and CI of relapse in the overall series
| Characteristics at diagnosis . | N . | 1-year NRM (95% CI) . | P value . | 1-year CI of relapse (95% CI) . | P value . |
|---|---|---|---|---|---|
| Age | <.001 | .76 | |||
| 17-60 y | 562 | 4% (2-6) | 29% (25-33) | ||
| >60 y | 229 | 9% (5-13) | 25% (19-31) | ||
| Gender | .46 | .72 | |||
| Male | 450 | 5% (3-7) | 28% (23-32) | ||
| Female | 341 | 7% (4-10) | 28% (23-33) | ||
| Diagnosis | .64 | .21 | |||
| DLBCL NOS | 540 | 6% (4-8) | 28% (24-32) | ||
| HGBCL DH/TH | 32 | 10% (0-21) | 34% (17-52) | ||
| HGBCL NOS | 27 | 5% (0-14) | 36% (19-54) | ||
| PMLBCL | 55 | 0% (NA) | 28% (16-40) | ||
| Transformed FL | 76 | 6% (0-11) | 22% (12-31) | ||
| DLBCL gray zone | 18 | 0% (NA) | 36% (13-59) | ||
| DLBCL T-cell rich | 20 | 5% (0-15) | 18% (0-36) | ||
| Other | 8 | 0% (NA) | 14% (0-40) | ||
| Ann Arbor stage | .6 | .99 | |||
| I-II | 168 | 2% (0-5) | 27% (20-33) | ||
| III-IV | 606 | 6% (4-8) | 28% (24-31) | ||
| B-symptoms | .82 | .71 | |||
| No | 405 | 4% (2-6) | 27% (23-32) | ||
| Yes | 354 | 7% (4-10) | 29% (24-34) | ||
| Bulky disease | .41 | .099 | |||
| No | 504 | 6% (4-8) | 29% (25-34) | ||
| Yes | 241 | 4% (2-7) | 26% (20-31) | ||
| Extranodal involvement | .28 | .12 | |||
| No | 286 | 5% (2-7) | 33% (28-39) | ||
| Yes | 464 | 6% (4-8) | 25% (21-29) | ||
| R-IPI | .042 | .47 | |||
| 0 | 42 | 0 (NA) | 20% (8-32) | ||
| 1-2 | 329 | 4% (2-6) | 27% (22-32) | ||
| 3-5 | 346 | 8% (5-10) | 29% (24-34) | ||
| Response after first line | .57 | .42 | |||
| CR | 443 | 5% (3-8) | 26% (22-30) | ||
| PR | 154 | 4% (1-7) | 28% (21-35) | ||
| SD | 45 | 5% (0-12) | 30% (16-44) | ||
| PD | 149 | 8% (3-12) | 33% (25-41) |
| Characteristics at diagnosis . | N . | 1-year NRM (95% CI) . | P value . | 1-year CI of relapse (95% CI) . | P value . |
|---|---|---|---|---|---|
| Age | <.001 | .76 | |||
| 17-60 y | 562 | 4% (2-6) | 29% (25-33) | ||
| >60 y | 229 | 9% (5-13) | 25% (19-31) | ||
| Gender | .46 | .72 | |||
| Male | 450 | 5% (3-7) | 28% (23-32) | ||
| Female | 341 | 7% (4-10) | 28% (23-33) | ||
| Diagnosis | .64 | .21 | |||
| DLBCL NOS | 540 | 6% (4-8) | 28% (24-32) | ||
| HGBCL DH/TH | 32 | 10% (0-21) | 34% (17-52) | ||
| HGBCL NOS | 27 | 5% (0-14) | 36% (19-54) | ||
| PMLBCL | 55 | 0% (NA) | 28% (16-40) | ||
| Transformed FL | 76 | 6% (0-11) | 22% (12-31) | ||
| DLBCL gray zone | 18 | 0% (NA) | 36% (13-59) | ||
| DLBCL T-cell rich | 20 | 5% (0-15) | 18% (0-36) | ||
| Other | 8 | 0% (NA) | 14% (0-40) | ||
| Ann Arbor stage | .6 | .99 | |||
| I-II | 168 | 2% (0-5) | 27% (20-33) | ||
| III-IV | 606 | 6% (4-8) | 28% (24-31) | ||
| B-symptoms | .82 | .71 | |||
| No | 405 | 4% (2-6) | 27% (23-32) | ||
| Yes | 354 | 7% (4-10) | 29% (24-34) | ||
| Bulky disease | .41 | .099 | |||
| No | 504 | 6% (4-8) | 29% (25-34) | ||
| Yes | 241 | 4% (2-7) | 26% (20-31) | ||
| Extranodal involvement | .28 | .12 | |||
| No | 286 | 5% (2-7) | 33% (28-39) | ||
| Yes | 464 | 6% (4-8) | 25% (21-29) | ||
| R-IPI | .042 | .47 | |||
| 0 | 42 | 0 (NA) | 20% (8-32) | ||
| 1-2 | 329 | 4% (2-6) | 27% (22-32) | ||
| 3-5 | 346 | 8% (5-10) | 29% (24-34) | ||
| Response after first line | .57 | .42 | |||
| CR | 443 | 5% (3-8) | 26% (22-30) | ||
| PR | 154 | 4% (1-7) | 28% (21-35) | ||
| SD | 45 | 5% (0-12) | 30% (16-44) | ||
| PD | 149 | 8% (3-12) | 33% (25-41) |
| Characteristics at ASCT . | N . | 1-year NRM (95% CI) . | P value . | 1-year CI of relapse (95% CI) . | P value . |
|---|---|---|---|---|---|
| Age | <.001 | .92 | |||
| 17-60 y | 501 | 4% (2-5) | 30% (26-34) | ||
| >60 y | 290 | 9% (6-13) | 25% (19-30) | ||
| Disease status at salvage therapy | .35 | .17 | |||
| Late relapse | 314 | 6% (3-9) | 24% (19-28) | ||
| Early relapse | 129 | 4% (0-8) | 32% (24-41) | ||
| Primary refractory | 348 | 6% (3-8) | 30% (25-35) | ||
| Time period | .31 | .22 | |||
| Before 30 October 2012 | 628 | 6% (4-8) | 27% (23-30) | ||
| Beyond 1 November 2012 | 163 | 6% (2-9) | 31% (24-39) | ||
| Second-line therapy | .45 | .74 | |||
| R-ESHAP | 442 | 6% (4-8) | 28% (24-32) | ||
| R-DHAP | 48 | 11% (2-20) | 35% (20-49) | ||
| R-ICE | 41 | 0% (NA) | 28% (14-42) | ||
| R-GDP | 38 | 0% (NA) | 14% (3-26) | ||
| Other | 195 | 6% (3-10) | 29% (22-36) | ||
| Conditioning regimen | .86 | .23 | |||
| BEAM | 628 | 5% (3-7) | 27% (24-31) | ||
| R-BEAM | 75 | 6% (0-11) | 30% (19-41) | ||
| Z-BEAM | 19 | 13% (0-29) | 50% (27-73) | ||
| TEAM | 4 | 100% (NA) | 25% (0-67) | ||
| Other | 49 | 9% (0-17) | 21% (10-33) | ||
| Treatment line at ASCT | .10 | <.001 | |||
| Second line | 617 | 5% (3-7) | 24% (20-27) | ||
| Third line | 147 | 8% (3-12) | 46% (38-55) | ||
| Front line in transformed | 27 | 4% (0-11) | 20% (4-35) |
| Characteristics at ASCT . | N . | 1-year NRM (95% CI) . | P value . | 1-year CI of relapse (95% CI) . | P value . |
|---|---|---|---|---|---|
| Age | <.001 | .92 | |||
| 17-60 y | 501 | 4% (2-5) | 30% (26-34) | ||
| >60 y | 290 | 9% (6-13) | 25% (19-30) | ||
| Disease status at salvage therapy | .35 | .17 | |||
| Late relapse | 314 | 6% (3-9) | 24% (19-28) | ||
| Early relapse | 129 | 4% (0-8) | 32% (24-41) | ||
| Primary refractory | 348 | 6% (3-8) | 30% (25-35) | ||
| Time period | .31 | .22 | |||
| Before 30 October 2012 | 628 | 6% (4-8) | 27% (23-30) | ||
| Beyond 1 November 2012 | 163 | 6% (2-9) | 31% (24-39) | ||
| Second-line therapy | .45 | .74 | |||
| R-ESHAP | 442 | 6% (4-8) | 28% (24-32) | ||
| R-DHAP | 48 | 11% (2-20) | 35% (20-49) | ||
| R-ICE | 41 | 0% (NA) | 28% (14-42) | ||
| R-GDP | 38 | 0% (NA) | 14% (3-26) | ||
| Other | 195 | 6% (3-10) | 29% (22-36) | ||
| Conditioning regimen | .86 | .23 | |||
| BEAM | 628 | 5% (3-7) | 27% (24-31) | ||
| R-BEAM | 75 | 6% (0-11) | 30% (19-41) | ||
| Z-BEAM | 19 | 13% (0-29) | 50% (27-73) | ||
| TEAM | 4 | 100% (NA) | 25% (0-67) | ||
| Other | 49 | 9% (0-17) | 21% (10-33) | ||
| Treatment line at ASCT | .10 | <.001 | |||
| Second line | 617 | 5% (3-7) | 24% (20-27) | ||
| Third line | 147 | 8% (3-12) | 46% (38-55) | ||
| Front line in transformed | 27 | 4% (0-11) | 20% (4-35) |
HGBCL, high-grade BCL.
Boldface values statistical significance.